282 related articles for article (PubMed ID: 10651946)
1. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.
Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Fujimoto J; Kakishita E
Immunology; 2000 Jan; 99(1):94-100. PubMed ID: 10651946
[TBL] [Abstract][Full Text] [Related]
2. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
Iwasaki T; Hamano T; Saheki K; Kuroiwa T; Kataoka Y; Takemoto Y; Ogata A; Sugihara A; Terada N; Fujimoto J; Kakishita E
Cell Immunol; 1999 Oct; 197(1):30-8. PubMed ID: 10555993
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
4. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.
Kataoka Y; Iwasaki T; Kuroiwa T; Seto Y; Iwata N; Hashimoto N; Ogata A; Hamano T; Kakishita E
Immunology; 2001 Jul; 103(3):310-8. PubMed ID: 11454060
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression.
Mori T; Nishimura T; Ikeda Y; Hotta T; Yagita H; Ando K
Blood; 1998 Jul; 92(1):101-7. PubMed ID: 9639505
[TBL] [Abstract][Full Text] [Related]
7. Differential requirement for IFN-gamma in CTL maturation in acute murine graft-versus-host disease.
Puliaev R; Nguyen P; Finkelman FD; Via CS
J Immunol; 2004 Jul; 173(2):910-9. PubMed ID: 15240678
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.
Baker MB; Riley RL; Podack ER; Levy RB
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1366-71. PubMed ID: 9037059
[TBL] [Abstract][Full Text] [Related]
9. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
[TBL] [Abstract][Full Text] [Related]
11. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.
Ellison CA; Fischer JM; HayGlass KT; Gartner JG
J Immunol; 1998 Jul; 161(2):631-40. PubMed ID: 9670937
[TBL] [Abstract][Full Text] [Related]
12. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy.
Stüber E; Büschenfeld A; von Freier A; Arendt T; Fölsch UR
Gut; 1999 Aug; 45(2):229-35. PubMed ID: 10403735
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.
van den Brink MR; Moore E; Horndasch KJ; Crawford JM; Murphy GF; Burakoff SJ
Transplantation; 2000 Jul; 70(1):184-91. PubMed ID: 10919598
[TBL] [Abstract][Full Text] [Related]
14. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
15. The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice.
Ellison CA; Natuik SA; McIntosh AR; Scully SA; Danilenko DM; Gartner JG
Immunology; 2003 Jul; 109(3):440-9. PubMed ID: 12807491
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts.
Delisle JS; Gaboury L; Bélanger MP; Tassé E; Yagita H; Perreault C
Blood; 2008 Sep; 112(5):2111-9. PubMed ID: 18552211
[TBL] [Abstract][Full Text] [Related]
17. Fas-mediated cytotoxicity by intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice.
Sakai T; Kimura Y; Inagaki-Ohara K; Kusugami K; Lynch DH; Yoshikai Y
Gastroenterology; 1997 Jul; 113(1):168-74. PubMed ID: 9207275
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Yaniv I; Shirwan H; Askenasy N
Stem Cells; 2007 Jun; 25(6):1448-55. PubMed ID: 17363551
[TBL] [Abstract][Full Text] [Related]
19. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
20. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
